The branded generics market in the Middle East & Africa is expected to grow from US$ 21.12 billion in 2022 to US$ 33.78 billion by 2028; it is estimated to grow at a CAGR of 8.1% from 2022 to 2028.
Generic medicines play a vital role in offering cost-effective treatment. A report by NCBI states that generic medicines are equivalent to the patent product in terms of dosage form, strength, administration route, quality, safety, performance characteristics, and intended use. A redalyc.org report states that physicians, pharmacists, and patients are key stakeholders in ensuring the success of generic medicines. Also, pharmacists, who in major instances serve as the first point of contact for patients, act as an important source of information about generic drugs. Thus, the rising use of branded generics by healthcare providers and professionals bolsters the growth of the Middle East & Africa branded generics market.
By introducing new features and technologies, vendors in the Middle East & Africa branded generics market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market at a good CAGR during the forecast period.
Middle East & Africa Branded Generics Market Segmentation
Middle East & Africa branded generics market is segmented into therapeutic application, distribution channel, drug class, formulation type and country. The therapeutic application segment of the Middle East & Africa branded generics market is segmented into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, and analgesics and anti-inflammatory. In 2022, the others segment held the largest share of the market, by therapeutic application. The Middle East & Africa branded generics market, by distribution channel is hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.
The retail pharmacies segment is likely to hold the largest share of the market in 2022. The Middle East & Africa branded generics market, by drug class is segmented into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic, and others. The others segment is likely to hold the largest share of the market in 2022. The Middle East & Africa branded generics market, based on formulation type is segmented into oral, parenteral, topical, and other. In 2022, the oral segment held the largest share of the market, by formulation type.
- Based on country, the Middle East & Africa branded generics market is segmented into Saudi Arabia, South Africa, UAE, and the Rest of Middle East & Africa. The Rest of MEA held the largest market share in 2022.
Aspen Holdings, AstraZeneca, Bausch Health (Valeant Pharmaceuticals), Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Hetero, Lupin, Mylan N.V., Par Pharmaceuticals, Sandoz International Gmbh, Sanofi, and Teva Pharmaceutical Industries Ltd. are among the leading companies in the branded generics market operating in this region.
Table of Contents
Companies Mentioned
- Aspen Holdings
- AstraZeneca
- Bausch Health (Valeant Pharmaceuticals)
- Dr. Reddy's Laboratories Inc.
- GlaxoSmithKline plc
- Hetero
- Lupin
- Mylan N.V.
- Par Pharmaceuticals
- Sandoz International Gmbh
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 174 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 21.12 Million |
| Forecasted Market Value ( USD | $ 33.78 Million |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Africa, Middle East |
| No. of Companies Mentioned | 12 |
